Therefore, the drug resistance of NB tumor cells to BET inhibitors is also occurred which hampers the clinical application of the BET inhibitors on NB patients (Felgenhauer et al., 2018; Iniguez et al., 2018). This evidence concerns the gene DNER and neoplasm.